NCT01866293 · OUTCOME

Overall Response Rate

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma · Source last updated 2017-08-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 1 year

What was measured

IMWG Criteria for Response, Progression and Relapse in Multiple Myeloma Patients

Analysis population: 9 participants are evaluable. 2 participants never started treatment.

Groups in this outcome

Cabozantinib (XL184)

Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cabozantinib (XL184)	11

Reported measurements

Source class 1

Progression of disease

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Cabozantinib (XL184)	2	Not reported	Not reported	Not reported	Not reported

Stable disease

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Cabozantinib (XL184)	6	Not reported	Not reported	Not reported	Not reported

N/A - off study before disease evaluation

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Cabozantinib (XL184)	1	Not reported	Not reported	Not reported	Not reported

Did not start study treatment

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Cabozantinib (XL184)	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
2
title
Progression of disease
measurements
group Id
OG000
value
6
title
Stable disease
measurements
group Id
OG000
value
1
title
N/A - off study before disease evaluation
measurements
group Id
OG000
value
2
title
Did not start study treatment

denoms

counts
group Id
OG000
value
11
units
Participants

description

IMWG Criteria for Response, Progression and Relapse in Multiple Myeloma Patients

groups

description
Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
id
OG000
title
Cabozantinib (XL184)

param Type

COUNT_OF_PARTICIPANTS

population Description

9 participants are evaluable. 2 participants never started treatment.

reporting Status

POSTED

time Frame

1 year

title

Overall Response Rate

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice